90 filings
8-K
NNMX
NANOMIX Corp
24 Nov 23
Departure of Directors or Certain Officers
4:20pm
8-K
NNMX
NANOMIX Corp
10 Mar 23
Regulation FD Disclosure
4:04pm
8-K
NNMX
NANOMIX Corp
25 Jan 23
Nanomix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer
4:43pm
8-K
NNMX
NANOMIX Corp
10 Nov 22
Unregistered Sales of Equity Securities
8:35am
8-K
NNMX
NANOMIX Corp
9 Sep 22
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
4:23pm
8-K
ivhso
29 Jul 22
Nanomix Announces Appoints Life Sciences Executive Thomas Schlumpberger as Chief Executive Officer and Member of the Board of Directors
3:57pm
8-K
myc9w8y
10 May 22
Nanomix Appoints Vidur Sahney as Chief Operating Officer
4:06pm
8-K
ckj iqjtacy8w9
24 Mar 22
Entry into a Material Definitive Agreement
9:13am
8-K
9v4a wsu20
2 Mar 22
Nanomix Completes 1-for-173 Reverse Stock Split
5:27pm
8-K
wvfg1
1 Mar 22
Entry into a Material Definitive Agreement
8:58am
8-K
e0pybrvby82bf
17 Nov 21
Other Events
12:00am
8-K
qpz5gah7bx7 0l2
5 Nov 21
Regulation FD Disclosure
5:06pm
8-K/A
prlm8 hqkf
5 Nov 21
Other Events
4:47pm
8-K
xo3f1901ta6hglfx
10 Sep 21
Amendments to Articles of Incorporation or Bylaws
2:05pm
8-K/A
omucv9ogbwafqph
27 Aug 21
Management’s Discussion and Analysis of Financial Condition and Results of Operations
12:00am
8-K
j2aar
29 Jun 21
Boston Therapeutics Announces $8.4 Million Convertible Placement
9:06am
8-K
gi7w4e4wbi 2x8
10 Jun 21
Entry into a Material Definitive Agreement
5:00pm
8-K
naawq ezjtojdlftpn
12 May 21
Entry into a Material Definitive Agreement
5:08pm
8-K
fuypxsnw5j9wemnmi
2 Feb 21
Entry into a Material Definitive Agreement
5:00pm
8-K
e7g x3hfox
15 May 20
Other Events
4:54pm